Results 311 to 320 of about 305,562 (334)
Some of the next articles are maybe not open access.
2021
Nonalcoholic fatty liver disease (NAFLD) is one of the major drivers for the rising trend in hepatocellular carcinoma (HCC). Over the past three decades, the incidence of both NAFLD and HCC have increased two- to threefold. It has been forecasted that the number of patients with NAFLD in the Unites States will reach 101 million by 2030; global increase
Bubu A, Banini, Arun J, Sanyal
openaire +2 more sources
Nonalcoholic fatty liver disease (NAFLD) is one of the major drivers for the rising trend in hepatocellular carcinoma (HCC). Over the past three decades, the incidence of both NAFLD and HCC have increased two- to threefold. It has been forecasted that the number of patients with NAFLD in the Unites States will reach 101 million by 2030; global increase
Bubu A, Banini, Arun J, Sanyal
openaire +2 more sources
Digestive Diseases and Sciences, 2010
Hepatocellular carcinoma (HCC) is a heterogeneous disease, with many poorly-defined prognostic patient subsets. Identification of discrete subsets will aid rational patient and treatment selection.A database with 778 biopsy-proven, unresectable and untransplantable HCC patients who were followed from diagnosis till death was interrogated.
Brian I, Carr +2 more
openaire +2 more sources
Hepatocellular carcinoma (HCC) is a heterogeneous disease, with many poorly-defined prognostic patient subsets. Identification of discrete subsets will aid rational patient and treatment selection.A database with 778 biopsy-proven, unresectable and untransplantable HCC patients who were followed from diagnosis till death was interrogated.
Brian I, Carr +2 more
openaire +2 more sources
FIBRONECTIN IN HUMAN HEPATOCELLULAR CARCINOMA (HCC) and HCC CELL LINES
Acta Pathologica Japonica, 1987The localization of fibronectin (FN) in human hepatocellular carcinoma (HCC) was studied in thirty‐six HCC tumors (19 autopsy and 17 surgical specimens), two xenografted tumors of HCC to BALB/c mice and three HCC cell lines. The synthesis of FN was also examined in three HCC cell lines. FN was demonstrated on the endothelial surface of the blood spaces
openaire +2 more sources
Scirrhous HCC: Another ‘omic thread in the HCC tapestry
Hepatology, 2023Joseph W. Franses, Dan G. Duda
openaire +2 more sources
2018
The majority of patients with hepatocellular cancer (HCC) present with advanced disease requiring palliative interventions. The approval of sorafenib in 2007 was a breakthrough in the treatment of advanced disease, and it has remained the standard first-line therapy for the past 10 years.
Alexa Childs, Tim Meyer
openaire +1 more source
The majority of patients with hepatocellular cancer (HCC) present with advanced disease requiring palliative interventions. The approval of sorafenib in 2007 was a breakthrough in the treatment of advanced disease, and it has remained the standard first-line therapy for the past 10 years.
Alexa Childs, Tim Meyer
openaire +1 more source
Inflammation of the liver, HCC development and HCC establishment
Hepatology InternationalTatsuo Kanda +2 more
openaire +2 more sources
Lactylation and HCC progression
Nature Reviews Gastroenterology & Hepatology, 2023openaire +2 more sources